Diabetic Microvascular Disease and Pulmonary Fibrosis: The Contribution of Platelets and Systemic Inflammation

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hyperglycemia 6 endocrinologydiseases
hyperlipidemia 1 endocrinologydiseases
obesity 5 endocrinologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
hyperglycemia 3486 diabetes. The risk of long-term diabetic complications in T1DM is high because of the potential for hyperglycemia throughout the lifetime of affected individuals. Type 2 DM (T2DM) that comprises the remainder, typically
hyperglycemia 3805 the coming years. Chronic metabolic abnormalities due to insulin deficiency or resistance, along with hyperglycemia , cause systemic oxidative stress and inflammation and impair antioxidant defense, leading to cardiovascular
hyperglycemia 4231 [[2],[5],[6],[7],[8],[9],[10]]. In addition to glycation of hemoglobin affecting oxygenation, chronic hyperglycemia may cause non-enzymatic glycation of the chest wall and bronchial collagen protein, leading to fibrotic
hyperglycemia 12371 Platelet hyperreactivity in diabetic patients has been reported as early as 1965 and is associated with hyperglycemia , hyperlipidemia, inflammatory and oxidant states and increased glycation of surface membrane proteins,
hyperglycemia 22922 expression is upregulated by many inducers of insulin resistance such as obesity, free fatty acids, hyperglycemia and oxidative stress (reviewed in [[68]]). Platelets of T2DM patients showed elevated levels of iNOS
hyperglycemia 26233 smooth muscle cells [[91]]. Therefore, the JAK/STAT signaling cascade may play a significant role in hyperglycemia -induced endothelial dysfunction in diabetes (Figure 4) [[91],[92]].There are 4 JAK (JAK 1–3 and Tyk2)
hyperlipidemia 12386 hyperreactivity in diabetic patients has been reported as early as 1965 and is associated with hyperglycemia, hyperlipidemia , inflammatory and oxidant states and increased glycation of surface membrane proteins, as well as higher
obesity 3649 Type 2 DM (T2DM) that comprises the remainder, typically develops later in life, is associated with obesity , and is expected to increase in prevalence in the coming years. Chronic metabolic abnormalities due
obesity 13224 upregulation of P2Y12 signaling, could be mitigated by improved glycemic control [[52]]. Dyslipidemia, obesity and systemic inflammation associated with T2DM may also contribute to platelet hyperreactivity. A clinical
obesity 22895 [[72],[74],[81],[82]]. iNOS expression is upregulated by many inducers of insulin resistance such as obesity , free fatty acids, hyperglycemia and oxidative stress (reviewed in [[68]]). Platelets of T2DM patients
obesity 26824 was recently reported that dysregulation of the JAK/STAT pathway contributes to the development of obesity and diabetes [[94]]. Targeted deletion of STAT3 in the brain in a rodent model leads to the development
obesity 26939 diabetes [[94]]. Targeted deletion of STAT3 in the brain in a rodent model leads to the development of obesity and diabetes mimicking the phenotype of ob/ob or db/db mice; however, these data have not yet been confirmed

You must be authorized to submit a review.